Cytosorbents Corporation (CTSO)
Chart Events
Performance Outlook
| Previous Close | 8.78 |
| Open | 8.82 |
| Bid | 8.63 x 3200 |
| Ask | 9.05 x 800 |
| Day's Range | 8.73 - 8.94 |
| 52 Week Range | 6.07 - 11.74 |
| Volume | 107,806 |
| Avg. Volume | 364,193 |
| Market Cap | 385.048M |
| Beta (5Y Monthly) | 0.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.20 |
| Earnings Date | Mar 09, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.75 |
- PR Newswire
CytoSorbents Announces Lease of New Global Headquarters in Princeton, New Jersey
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces the lease of its new global headquarters in Princeton, NJ. On March, 26, 2021, the company entered into a new agreement with National Business Parks to lease approximately 48,500 square feet located at 305 College Road East at Princeton Forrestal Village in Princeton, New Jersey. The mixed-use facility is expected to accommodate all U.S. administrative, clinical, commercialization, manufacturing, and research and development activities. The 15-year lease is expected to commence on June 1, 2021, subject to certain conditions.
- PR Newswire
CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for U.S. Trial on Ticagrelor Removal During Cardiothoracic Surgery
CytoSorbents Corporation (NASDAQ: CTSO) announces the filing of an Investigational Device Exemption (IDE) application to conduct the clinical study, "Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)," in the United States to support an initial FDA regulatory approval. This is being done under the previously announced FDA Breakthrough Designation granted for the removal of ticagrelor in a cardiopulmonary bypass circuit during urgent and emergent cardiac surgery.
- PR Newswire
CytoSorbents to Present at the Oppenheimer 31st Annual Healthcare Conference
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces its participation the Oppenheimer 31st Annual Healthcare Conference. Chief Executive Officer, Dr. Phillip Chan, MD, PhD will present an overview of the Company's progress and outlook. Company management will also meet with investors in 1x1 meetings throughout the day. To schedule a meeting with management, please contact your Oppenheimer representative.
